Loading...
XNAS
NAGE
Market cap271mUSD
Jul 09, Last price  
3.49USD
1D
3.56%
1Q
-22.44%
Jan 2017
5.44%
IPO
-61.22%
Name

Chromadex Corp

Chart & Performance

D1W1MN
XNAS:NAGE chart
P/E
15.61
P/S
EPS
0.22
Div Yield, %
Shrs. gr., 5y
6.95%
Rev. gr., 5y
16.56%
Revenues
0k
-100.00%
004,506,0005,778,0007,566,0008,113,00011,610,00010,161,00015,313,00017,885,00026,811,00021,201,00031,557,00046,291,00059,257,00067,449,00072,050,00083,570,00099,597,0000
Net income
17m
+103.30%
-1,438-38,382-2,104,000-908,000-2,052,000-7,895,000-11,662,000-4,420,000-5,388,000-2,771,000-2,928,000-11,378,000-33,316,000-32,147,000-19,925,000-27,128,000-16,540,000-4,938,0008,550,00017,382,000
CFO
14m
+11.52%
-38,483-1,921,371-396,172-2,661,550-4,098,829-10,119,713-3,906,011-2,580,406-2,111,138-2,936,596-9,804,178-20,908,000-20,439,000-10,600,000-24,163,000-15,098,0007,117,00012,109,00013,504,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT